Feature | August 11, 2010

Small BiVAD Used in Emergency Case as Twin, Heart Booster Pumps

James Armstrong recently became the first patient in North America to be implanted with two Heartware ventricular assist devices.

August 11, 2010 – The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware VADs have been implanted in the left and right ventricles anywhere in North America, which is a "game changer" in the realm of heart assist devices, according to Patrick M. McCarthy, M.D., chief of the hospital's division of cardiac surgery and director of the hospital's Bluhm Cardiovascular Institute.

"The world doesn't need the artificial heart anymore," said McCarthy, who is also the Heller-Sacks professor of surgery at Northwestern University Feinberg School of Medicine. "The goal is total support of the heart. This biventricular approach achieves that without cutting out the patient's own heart, which is what happens with artificial heart implants."

According to Edwin McGee Jr. M.D., surgical director for the Bluhm Institute's heart transplant and assist device program and the lead cardiac surgeon who performed the implant, when the patient, 44-year-old James Armstrong, was transferred to Northwestern Memorial just weeks ago, he was near death with an aggressive state of myocarditis. Myocarditis is a severe inflammation of the heart tissue that--in some rare cases--can be fatal when unaddressed.

Only about a dozen times before in Europe had the twin implant of the small Heartware VAD been performed, and now the approach would be Armstrong's best chances for survival. The Heartware VAD is under trial in the United States as an LVAD. Armstrong did not qualify for the current trial and was able to have the device implanted under a process known as "emergency use". Emergency use is defined as the use of an investigational article with a human subject in a life-threatening situation. Although such uses are not yet approved by the U.S. Food and Drug Administration, they are allowed when there is no standard acceptable treatment available and there is not sufficient time to obtain approval from an institutional review board.

"As we do for all of our patients, we wanted the very best for Jim," said McGee. "Standard BiVAD pumps sit outside of the body and are plagued by an extremely high complication and mortality rate."

McGee added that another reason to study this system is because the configuration leaves patients' hearts intact. This, he says, lends itself to the possibility that in some rare cases the heart may actually recover. "Naturally, that remains to be seen — but it's possible," he said. This probability is obliterated with artificial hearts because essential components of the natural heart are removed.

McGee adds that one of the greatest advantages to patients is that the pumps are contained (implanted) completely within the chest. There are two small controlling leads in the body that connect to a small monitor and power source outside the body that can be carried in two small shoulder pouches.

"Using this device in a biventricular support configuration may offer total heart support to more individuals with improved quality of life and hopefully fewer complications, than with the currently approved devices," added McGee.

The American Heart Association estimates that an average of 300,000 people die every year from heart failure--and roughly 10,000 of them qualify for heart transplant. Due to lack of donor organs roughly only 2,000 cardiac transplants are performed each year. Assist devices such as the ones Armstrong received are becoming an increasingly important therapy to help individuals with advanced heart failure.

Dr. McGee is a paid consultant for HeartWare.

For more information: www.nmh.org

Related Content

Aortix device, TCT, Interventional Innovation Shark Tank Competition, catheter-based circulatory heart pump

Image courtesy of Procyrion

News | Ventricular Assist Devices (VAD)| October 06, 2015
The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in...
Procyrion, Aortix device, grand prize, Create the Future Design Contest

Aortix device image courtesy of Procyrion Inc.

News | Ventricular Assist Devices (VAD)| October 05, 2015
Procyrion Inc. of Houston has been awarded the grand prize of $20,000 in the 2015 "Create the Future" Design Contest...
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Johns Hopkins, sticky gel, stem cells, rat hearts, heart attacks

Hydrogel applied to beating rat hearts improves stem cell uptake by the heart muscle and speeds up tissue healing after heart attack. Image courtesy of Johns Hopkins Medicine.

News | Stem Cell Therapies| September 29, 2015
A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and...
American Heart Association, AHA, heart failure, HF, Rise Above Heart Failure initiative, report
News | Heart Failure| September 29, 2015
September 29, 2015 — A new report from the American Heart Association (AHA) projects that the number of Americans dia
Zoll, acquires, Kyma Medical Technologies, LifeVest, µ-Cor System, heart failure, remote monitoring

µ-Cor System image courtesy of Kyma Medical Technologies

News | Remote Monitoring| September 21, 2015
Zoll Medical Corp. announced that it has acquired Tel Aviv, Israel-based Kyma Medical Technologies Ltd., which develops...
Freedom Driver, SynCardia, recall, Total Artificial Heart, TAH-t, part failure

Freedom Driver attached to Total Artificial Heart. Image courtesy of SynCardia.

News | Ventricular Assist Devices (VAD)| September 18, 2015
SynCardia Systems initiated a Class I recall of the Freedom Driver Systems used with the company’s temporary Total...
ICER, CardioMEMS, Entresto, congestive heart failure, cost-effectiveness

CardioMEMS image courtesy of St. Jude Medical.

News | Heart Failure| September 16, 2015
The Institute for Clinical and Economic Review (ICER) has released a new report offering a comprehensive review of...
Thoratec, HeartMate II LVAS, Urgent Device Correction Letter, Pocket System Controller, backup battery
News | Ventricular Assist Devices (VAD)| September 16, 2015
Thoratec Corp. issued a voluntary Urgent Medical Device Correction Letter to all hospitals who have patients supported...
Michigan, See You in 7, heart failure, readmissions, ACC
News | Patient Engagement| September 15, 2015
Michigan hospitals participating in the American College of Cardiology’s “See You in 7” program demonstrated important...
Overlay Init